Source comparison
How Long CJC-1295 no DAC & Ipamorelin Takes to Work: Research Protocol Comparison
Initial GH Release Onset 30 minutes 20–40 minutes 20–30 minutes Combined administration produces earlier onset due to dual-pathway activation Peak Plasma GH Concentration 1–2 hours 40–60 minutes 1–1.5 hours Synergistic effect results in 3–5× higher GH peaks th
This comparison does not assign a generated winner or score.
- Initial GH Release Onset
- 30 minutes
- 20–40 minutes
- 20–30 minutes
- Combined administration produces earlier onset due to dual-pathway activation
- Peak Plasma GH Concentration
- 1–2 hours
- 40–60 minutes
- 1–1.5 hours
- Synergistic effect results in 3–5× higher GH peaks than monotherapy
- Duration of Elevated GH
- 3–4 hours
- 2–3 hours
- Pulse duration governed by CJC-1295's longer half-life when co-administered
- Cortisol Elevation Risk
- Minimal
- Negligible
- Ipamorelin's receptor selectivity prevents cortisol spike seen with GHRP-2/6
- Time to Measurable Body Composition Change
- 10–14 weeks
- 12–16 weeks
- 8–12 weeks
- Combined protocols produce earlier phenotypic changes due to higher cumulative GH exposure
- Dosing Frequency for Sustained Effect
- 2–3× daily
- Pulsatile dosing (mimicking natural GH secretion) superior to single daily dose
- The comparison makes clear: while both peptides initiate GH release within the first hour, the timeline to observable research outcomes is measured in weeks, not hours. Researchers using combined protocols see earlier body composition shifts because cumulative GH exposure over 8–12 weeks is higher. Not because the peptides 'work faster' acutely.